Clinical trials: Dysthyroid Orbitopathy
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.
- Trial name
- NCT00424151
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Silkiss, Rona Z., M.D., FACS
Thyroid-Associated Ophthalmopathy
99Tc-MDP for Thyroid-Associated Ophthalmopathy
To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.
- Trial name
- NCT03948191
- Testing
- Methylprednisolone, 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Dalian University
Thyroid Eye Disease, Eyelid Diseases
Tamsulosin for Thyroid Lid Retraction
The purpose of this study is to examine the effect of using Tamsulosin for treatment of eyelid retraction as part of thyroid eye disease.
- Trial name
- NCT04359979
- Testing
- Tamsulosin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Graves Disease, Graves Ophthalmopathy
Heart Rhythm After Intravenous Methylprednisolone Administration
High doses of intravenous (iv.) glucocorticoids (GCs) are commonly used as a treatment for many autoimmune and inflammatory disorders.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Heart Rhythm Disorder, Hypertension
- Trial name
- NCT04391439
- Testing
- Intravenous Methylprednisolone
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Thyroid-Associated Ophthalmopathy
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity.
- Trial name
- NCT06927375
- Testing
- Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Thyroid Eye Disease, TED
Psychological Burden of Thyroid Eye Disease
This interview study aims to look in depth at the quality of life of people living with TED and their caregivers, with emphasis on impact on mood, relationships, work/education, and leisure.
- Trial name
- NCT07444190
- Testing
- focus groups and individual interviews as well as filling out questionnaires
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Dry Eye Disease (DED), Graves Ophthalmopathy
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease
This prospective, interventional, randomized, controlled, double-blind clinical study evaluates the effect of Low-Level Light Therapy (LLLT) delivered by a polychromatic periocular mask (Eye-light®️) versus a sham device in…
- Trial name
- LLLT-Graves (NCT07332988)
- Testing
- Low Light Level therapy
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Thyroid Orbitopathy
Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy
Background: The activity of thyroid orbitopathy can be evaluated with CAS (Clinical Activity Score) based on 7 inflammatory signs.
- Trial name
- NCT03891043
- Testing
- Selenium
- Volunteers
- 33 people
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Thyroid Eye Disease, Ocular Hypertension
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients.
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Trial name
- NCT01927406
- Testing
- Prostaglandin Analog, Timolol
- Where
- United States
- Sponsor
- Stanford University
Graves Ophthalmopathy, Graves Disease
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).
- Conditions
- Graves Ophthalmopathy, Graves Disease, Eye Diseases, Thyroid Diseases
- Trial name
- NCT01727973
- Testing
- Doxycycline
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sun Yat-sen University
Exophthalmos, Orbitopathy, Graves
Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy
The described technique of DLW-PRS decompression for TRO using SONOPET(R) appears to be safe and effective, reducing the complications associated with decompressing the orbital floor and medial wall.
- Conditions
- Exophthalmos, Orbitopathy, Graves, Surgery
- Trial name
- NCT04025034
- Testing
- Orbital decompression with ultrasonic bone removal
- Volunteers
- 35 people
- Sponsor
- Hospital Universitario 12 de Octubre
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05524571
- Testing
- Batoclimab
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Associated Ophthalmopathies
MHB018A Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants…
- Trial name
- NCT06989918
- Testing
- MHB018A
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial…
- Trial name
- HAZEL 401 (NCT07438405)
- Testing
- AMG 732
- Where
- 8 sites in United States, Poland and 2 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Graves' Ophthalmopathy
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
- Trial name
- NCT01969019
- Testing
- methylprednisolone, prednisone
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid-associated Ophthalmopathy
Trial of Rituximab for Graves' Ophthalmopathy
This study is being done to investigate the effects (good and bad) of Rituximab for the treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven to be difficult to treat.
- Trial name
- NCT00595335
- Testing
- Rituximab, Saline, Methylprednisolone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rebecca Bahn
Thyroid Associated Ophthalmopathy
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients.
- Trial name
- ORGO (NCT03098225)
- Testing
- Orbital radiotherapy, Methylprednisolone
- Volunteers
- 120 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Trial name
- NCT06401044
- Testing
- AMG 732
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Amgen